---
title: "Lakewood-Amedex Biotherapeutics surges 75% in regular trading"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293509846.md"
description: "Lakewood-Amedex Biotherapeutics (LABT) jumped 75% to $3.26 during regular trading, hitting a high of $3.48."
datetime: "2026-07-22T18:51:19.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293509846.md)
  - [en](https://longbridge.com/en/news/293509846.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293509846.md)
---

# Lakewood-Amedex Biotherapeutics surges 75% in regular trading

Lakewood-Amedex Biotherapeutics(LABT.US) 盘中涨超**75%**，现报**3.256 美元**。

该股在常规交易时段曾一度飙升至**3.48 美元**，涨幅达**87%**，触发 5 分钟急涨警报，成交量高达**7120 万股**。

根据媒体报道，Lakewood-Amedex Biotherapeutics 被列入当日盘中波动最显著的 12 只医疗保健类股票之一，涨幅位居前列。

### Related Stocks

- [LABT.US](https://longbridge.com/en/quote/LABT.US.md)

## Related News & Research

- [Lakewood-Amedex Biotherapeutics flags new press release available on Nu-3 resistance data](https://longbridge.com/en/news/293470541.md)
- [Lakewood-Amedex Biotherapeutics makes Investor Deck public, Nu-3 Phase 2a planned with IND open](https://longbridge.com/en/news/292813307.md)
- [08:02 ETLakewood-Amedex Expands Global IP Portfolio for Lead Candidate, Nu-3, Targeting Infected Diabetic Foot Ulcers](https://longbridge.com/en/news/287767752.md)
- [Lakewood-Amedex Biotherapeutics Inc. 1Q 2026: Revenue ($886.75K), EPS ($0.2) — 10-Q Summary](https://longbridge.com/en/news/287405274.md)
- [Top Biotech Gainers: ZCMD Surges 190%, LABT Advances On Nu-3 Progress, ARWR Hits The Targets](https://longbridge.com/en/news/293552010.md)